Agilent completes $240 million cash acquisition of digital‑pathology software firm Proscia
+1 new source since this summary was written
Agilent Technologies closed its purchase of Proscia, paying $240 million in cash with an additional $30 million possible if performance targets are met. Proscia, a provider of digital‑pathology software, has been placed within Agilent’s Life Sciences and Diagnostics Markets division. The deal was announced by President and CEO Padraig McDonnell, who said it strengthens Agilent’s pathology portfolio and adds a recurring‑revenue software business. Agilent reported FY 2025 revenue of $6.95 billion and employs about 18,000 people worldwide.
Why it matters
The company says the acquisition adds a recurring‑revenue software business to its pathology portfolio, which could broaden future earnings streams. The additional $30 million contingent payment may increase total outlay if milestones are achieved.
Key facts
- 1Agilent paid $240 million in cash for Proscia. tradingview.com
- 2Up to $30 million in extra payments are tied to future performance milestones. tradingview.com
- 3Proscia provides digital‑pathology software for clinical and life‑sciences customers. investing.com
- 4Proscia has been placed within Agilent’s Life Sciences and Diagnostics Markets division. investing.com
- 5Padraig McDonnell, Agilent President and CEO, said the deal strengthens the pathology portfolio. investing.com
- 6Agilent generated $6.95 billion in revenue in fiscal year 2025. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.